Gilead Sciences Inc diskutieren
Gilead Sciences Inc
WKN: 885823 / Symbol: GILD / Name: Gilead Sciences / Aktie / Biotechnologie & medizinische Forschung / Large Cap /
102,58 €
-2,92 %
Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Daiwa Capital Markets from a "neutral" rating to an "outperform" rating. They now have a $128.00 price target on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) was upgraded by analysts at Daiwa America from a "hold" rating to a "strong-buy" rating.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at JPMorgan Chase & Co. from $135.00 to $145.00. They now have an "overweight" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Rothschild & Co Redburn from $136.00 to $143.00. They now have a "buy" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Citigroup Inc. from $125.00 to $135.00. They now have a "buy" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Cantor Fitzgerald from $129.00 to $135.00. They now have an "overweight" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at BMO Capital Markets from $130.00 to $135.00. They now have an "outperform" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at TD Cowen from $115.00 to $125.00. They now have a "buy" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Wolfe Research from $135.00 to $140.00. They now have an "outperform" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Wells Fargo & Company from $140.00 to $145.00. They now have an "overweight" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Morgan Stanley from $143.00 to $147.00. They now have an "overweight" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at JPMorgan Chase & Co. from $145.00 to $150.00. They now have an "overweight" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its "outperform" rating reaffirmed by analysts at Sanford C. Bernstein.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its "buy" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $145.00 price target on the stock, up previously from $127.00.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Argus from $130.00 to $135.00. They now have a "buy" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Daiwa Capital Markets from $128.00 to $129.00. They now have an "outperform" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Needham & Company LLC from $133.00 to $140.00. They now have a "buy" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Mizuho from $131.00 to $140.00. They now have an "outperform" rating on the stock.
Ratings data for GILD provided by MarketBeat
Gilead Sciences (NASDAQ:GILD) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $140.00 price target on the stock.
Ratings data for GILD provided by MarketBeat
Neueste Beiträge
JPMorgan_Chase___Co_ in Amazon.com Inc. diskutieren